【摘要】

目的通过比较辛伐他汀联合尼莫地平与单纯尼莫地平治疗血管性痴呆患者临床疗效及对其认知功能影响来为临床治疗选择提高参考。
方法按照随机数字表法将80例血管性痴呆者分组为对照组与观察组,各40例。对照组采用尼莫地平治疗;观察组于对照组治疗基础上加用辛伐他汀治疗。观察两组患者治疗前、后认知功能及日常生活能力评分变化、不良反应。
结果两组患者治疗后MMSE各项评分及ADL评分均较治疗前明显改善,但观察组各项评分改善较对照组显著,P<0.05;观察组不良反应者1例,不良反应率为2.5%略低于对照组2例,5.0%,P>0.05。
结论相比单纯尼莫地平治疗血管性痴呆患者来说,应用辛伐他汀联合尼莫地平治疗可更好地改善患者认知功能,提高其日常生活质量,且不良反应少,因此值得进一步研究与推广。

【Abstract】

Objective To improve the clinical treatment options for comparison with simvastatin alone nimodipine nimodipine treatment of vascular dementia and its effects on the clinical efficacy of cognitive function reference, in order to better improve the prognosis of patients and improve their quality of life.
Methods According to a random number table diagnostic period - January 2014 to May 2012 were 80 cases of vascular dementia group was the control group and the observation group, 40 cases respectively. The control group with nimodipine, 20mg / time, 3 times / day; while conventional antihypertensive and antidiabetic and anticoagulant therapy. Observation group therapy based on the use of simvastatin treatment in the control group, 20mg / day, both groups were treated for 6 consecutive months. Were observed before and after treatment of cognitive function and activities of daily living score changes, adverse reactions.
Results After treatment the MMSE score and ADL scores than before treatment significantly improved, but the observation group than in the control group, the scores improved significantly, with statistical significance, P<0.05; one cases of adverse reactions were observed group, adverse reactions rate of 2.5% was slightly lower than in the control group 2 cases, 5.0%, but not statistically significant, P>0.05.
Conclusion   Compared to pure nimodipine treatment of vascular dementia patients, simvastatin nimodipine therapy can improve cognitive function in patients better and improve their quality of daily life, and fewer adverse reactions, and therefore worthy of further research and promotion.